As drugmakers seek ways to elude IL-2 flaws, Clinigen secures the full rights to original troubled IL-2 drug Proleukin
Proleukin, the troubled IL-2 cancer drug sold by Novartis, has found a new home at Clinigen, while others in the field of immuno-oncology seek …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
